Plecanatide
Brand names: Trulance · Active ingredient: Plecanatide
In short: TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C).
What is Plecanatide used for?
TRULANCE is indicated in adults for the treatment of:
chronic idiopathic constipation (CIC).
irritable bowel syndrome with constipation (IBS-C).
⚠ Boxed warning (FDA's strongest warning)
TRULANCE is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice, administration of a single oral dose of plecanatide caused deaths due to dehydration
.
Avoid use of TRULANCE in patients 6 years to less than 18 years of age
.
The safety and effectiveness of TRULANCE have not been established in patients less than 18 years of age
.
Plecanatide dosage
The recommended dosage of TRULANCE for the treatment of CIC and IBS-C is 3 mg taken orally once daily.
Take TRULANCE with or without food
.
If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take two doses at the same time.
Swallow a tablet whole for each dose.
For adult patients with swallowing difficulties, TRULANCE tablets can be crushed and administered orally either in applesauce or with water or administered with water via a nasogastric or gastric feeding tube. Mixing TRULANCE crushed tablets in other soft foods or in other liquids has not been tested.
Oral Administration in Applesauce:
In a clean container, crush the TRULANCE tablet to a powder and mix with 1 teaspoonful of room temperature applesauce.
Consume the entire tablet-applesauce mixture immediately. Do not store the mixture for later use.
Oral Administration in Water:
Place the TRULANCE tablet in a clean cup.
Pour approximately 30 mL of room temperature water into the cup.
Mix by gently swirling the tablet and water mixture for at least 10 seconds. The TRULANCE tablet will fall apart in the water.
Swallow the entire contents of the tablet-water mixture immediately.
If any portion of the tablet is left in the cup, add another 30 mL of water to the cup, swirl for at least 10 seconds, and swallow immediately.
Do not store the tablet-water mixture for later use.
Administration with Water via a Nasogastric or Gastric Feeding Tube:
Place the TRULANCE tablet in a clean cup with 30 mL of room temperature water.
Mix by gently swirling the tablet and water mixture for at least 15 seconds. The TRULANCE tablet will fall apart in the water.
Flush the nasogastric or gastric feeding tube with 30 mL of water using a catheter tip syringe.
Draw up the mixture using the syringe and immediately administer via the nasogastric or gastric feeding tube. Do not reserve for future use.
If any portion of the tablet is left in the cup, add another 30 mL of water to the cup, swirl for at least 15 seconds, and using the same syringe, administer via the nasogastric or gastric feeding tube.
Using the same or a fresh syringe, flush the nasogastric or gastric feeding tube with at least 10 mL of water.
How to take Plecanatide — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Advise patients:
Diarrhea
To stop TRULANCE and contact their healthcare provider if they experience severe diarrhea
.
Accidental Ingestion
Accidental ingestion of TRULANCE in children, especially in children less than 6 years of age, may result in severe diarrhea and dehydration. Instruct patients to take steps to store TRULANCE securely and out of reach of children and to dispose of unused TRULANCE
.
Administration and Handling Instructions
To take TRULANCE once daily with or without food
.
If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take two doses at the same time.
To swallow TRULANCE tablets whole.
If adult patients have swallowing difficulties, TRULANCE tablets can be crushed and administered orally in either applesauce or with water, or administered with water via a nasogastric or gastric feeding tube, as described in the Medication Guide.
To keep TRULANCE in a dry place. Protect from moisture. Keep TRULANCE in the original bottle. Do not remove desiccant from the bottle. Do not subdivide or repackage. …
Warnings & precautions
Do not take this medicine if: TRULANCE is contraindicated in:
Patients less than 6 years of age due to the risk of serious dehydration
.
Patients with known or suspected mechanical gastrointestinal obstruction.
TRULANCE is contraindicated in patients less than 6 years of age. The safety and effectiveness of TRULANCE in patients less than 18 years of age have not been established. In young juvenile mice (human age equivalent of approximately 1 month to less than 2 years), plecanatide increased fluid-secretion into the intestines as a consequence of stimulation of guanylate cyclase-C (GC-C), resulting in mortality in some mice within the first 24 hours, apparently due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop severe diarrhea and its potentially serious consequences.
Avoid the use of TRULANCE in patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in younger mice and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of TRULANCE in patients 6 years to less than 18 years of age
[see
Contraindications (4),
Warnings and Precautions (5.2),
Use in Specific Populations (8.4)]
.
Diarrhea was the most common adverse reaction in four placebo-controlled clinical trials, two in patients with CIC and two in patients with IBS-C. Severe diarrhea was reported in 0.6% of patients in two trials in patients with CIC and in 0.6% of patients in the two trials in patients with IBS-C
. If severe diarrhea occurs, suspend dosing and rehydrate the patient.
Plecanatide side effects
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Demographic characteristics were comparable between the TRULANCE and placebo groups in all studies
.
Chronic Idiopathic Constipation (CIC)
The safety data described below reflect data from 1,733 adult patients with CIC randomized in two double-blind, placebo-controlled clinical trials (Study 1 and Study 2) to receive placebo or 3 mg of TRULANCE once daily for 12 weeks.
Most Common Adverse Reactions
Table 1 provides the incidence of adverse reactions reported in at least 2% of CIC patients in the TRULANCE-treated group and at an incidence that was greater than in the placebo group.
Adverse Reaction | TRULANCE, 3 mg
(N = 863)
% | Placebo
(N = 870)
%
a:Reported in at least 2% of TRULANCE-treated patients with CIC and at an incidence greater than placebo.
b:Verbatim reports of diarrhea were recorded as adverse reactions; reports of loose stools and increase in stool frequency were recorded as adverse reactions if they were also reported to be bothersome to the patient.
Diarrheaᵇ | 5 | 1
Diarrhea
The majority of reported cases of diarrhea occurred within 4 weeks of treatment initiation. Severe diarrhea was reported in 0.6% of TRULANCE-treated patients compared to 0.3% of placebo-treated patients. …
About this medicine
TRULANCE (plecanatide) is a guanylate cyclase-C (GC-C) agonist. Plecanatide is a 16 amino acid peptide with the following chemical name: L-Leucine, L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-cysteinyl-L-α-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (4→12),(7→15)-bis(disulfide).
The molecular formula of plecanatide is C
65H
104N
18O
26S
4and the molecular weight is 1682 Daltons. The amino acid sequence for plecanatide is shown below:
The solid lines linking cysteines illustrate disulfide bridges.
Plecanatide is an amorphous, white to off-white powder. It is soluble in water. TRULANCE tablets are supplied as 3 mg tablets for oral administration. The inactive ingredients are magnesium stearate and microcrystalline cellulose.
How it works: Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fe2895bf-71a6-493a-b0ca-e06b2dfefc82. Read the full official label on DailyMed.
Related medicines
Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate